ReviewDiagnostics (Basel, Switzerland)2022
Neutrophils and Asthma.
Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 61 citations in OpenAlex.
- Targeting Type 2 and Non-type 2 Asthma: Emerging Biologics and Personalized Strategies.Current allergy and asthma reports · 2026Review
- Triggering mechanisms of acute thunderstorm asthma: epithelial barrier disruption and immune dysregulation.Respiratory research · 2026Review
- Plant MicrofungiInternational journal of molecular sciences · 2026Article
- Recent Advances and New Therapeutic Goals in the Management of Severe Asthma.Internal medicine (Tokyo, Japan) · 2026Review
- Targeting neutrophil extracellular traps: an emerging strategy for improving the management of refractory asthma.Frontiers in medicine · 2026Article
- Fasudil improves neutrophilic asthma by influencing M1 macrophage polarization and the expression of the NF-κB/TLR-2/RPS3 pathway.American journal of translational research · 2026Article
- Neutrophil Plasticity in Airway Disease: Balancing Damage and Repair.Journal of innate immunity · 2026Review
- Neutrophil Heterogeneity in Airway Inflammatory Diseases.Inflammation · 2025Review
- Early-life viral infections and asthma: new cells and ideas.Current opinion in pediatrics · 2025Review
- Associations of inflammatory burden index with the prevalence and mortality of asthma in adults: a population based study.Journal of thoracic disease · 2025Article
- Long-Term Administration of BTH2 Hypoallergenic Vaccine Candidate Induces Hallmarks of Allergen Immunotherapy in Murine Model ofBiomedicines · 2025Article
- Neutrophilic Asthma-From Mechanisms to New Perspectives of Therapy.Journal of clinical medicine · 2025Review
- Observational
- The Role of Alarmins in the Pathogenesis of Asthma.Biomolecules · 2025Review
- Distinct Roles Between Eotaxin 1 and Eotaxin 2 in Asthmatic Airways.Clinical and translational allergy · 2025Article
- MicrofungusCells · 2025Article
- CCR3 deficiency shifts adaptive to innate-driven immunity in asthma.The journal of allergy and clinical immunology. Global · 2025Article
- Review
- Targeting alarmins in asthma: From bench to clinic.The Journal of allergy and clinical immunology · 2025Review
- Monocyte CCL2 signaling possibly contributes to increased asthma susceptibility in type 2 diabetes.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although eosinophilic inflammation is characteristic of asthma pathogenesis, neutrophilic inflammation is also marked, and eosinophils and neutrophils can coexist in some cases. Based on the proportion of sputum cell differentiation, asthma is classified into eosinophilic asthma, neutrophilic asthma, neutrophilic and eosinophilic asthma, and paucigranulocytic asthma. Classification by bronchoalveolar lavage is also performed. Eosinophilic asthma accounts for most severe asthma cases, but neutrophilic asthma or a mixture of the two types can also present a severe phenotype. Biomarkers for the diagnosis of neutrophilic asthma include sputum neutrophils, blood neutrophils, chitinase-3-like protein, and hydrogen sulfide in sputum and serum. Thymic stromal lymphoprotein (TSLP)/T-helper 17 pathways, bacterial colonization/microbiome, neutrophil extracellular traps, and activation of nucleotide-binding oligomerization domain-like receptor family, pyrin domain-containing 3 pathways are involved in the pathophysiology of neutrophilic asthma and coexistence of obesity, gastroesophageal reflux disease, and habitual cigarette smoking have been associated with its pathogenesis. Thus, targeting neutrophilic asthma is important. Smoking cessation, neutrophil-targeting treatments, and biologics have been tested as treatments for severe asthma, but most clinical studies have not focused on neutrophilic asthma. Phosphodiesterase inhibitors, anti-TSLP antibodies, azithromycin, and anti-cholinergic agents are promising drugs for neutrophilic asthma. However, clinical research targeting neutrophilic inflammation is required to elucidate the optimal treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.